Radiopharmaceuticals

Healthcare professionals

 


Product


Description

Summary
of Product Characteristic

 

Axumin

Positron emission tomography (PET) tracer for detection of prostate cancer recurrence suspected by elevated blood prostate specific antigen levels
Summary of Product Characteristic
Axumin 1600 MBq/ml or 3200 MBq/ml
 

 

Fludeoxyglucose (18F) Synektik

Tracer for use with positron emission tomography (PET) in oncological, cardiological, neurological, and infectious and inflammatory diseases diagnostic procedures
Summary of Product Characteristic Fludeoxyglucose (18F) Synektik 200-2200 MBq/ml

 

Fluorocholine (18F) Synektik


Tracer for use with positron emission tomography (PET) in detection of bone metastases of prostate cancer and hepatocellular carcinoma

Summary of Product Characteristic

Fluorocholine (18F) Synektik 1 GBq/ml


GalliaPharm
Ge-68/Ga-68 generator


Pharmaceutical product for obtaining the positron emitter Gallium (68) for production of labelled tracers (for example peptides)

Summary of Product Characteristic
GalliaPharm, 0.74-1.85 GBq, radionuclide generator

 

Glunektik

Tracer for use with positron emission tomography (PET) in oncological, cardiological and neurological diagnostic procedures and infectious and inflammatory diseases
Summary of Product Characteristic
Glunektik 1 GBq/ml

 

IASOdopa


Tracer for use with positron emission tomography (PET) in oncological and neurological diagnostic procedures

Summary of Product Characteristic
IASOdopa 0.3 GBq/ml

 

IASOglio


Tracer for use with positron emission tomography (PET) when enhanced amino acids  consumption of sick organs or tissues is the diagnostic target

Summary of Product Characteristic
IASOglio 2 GBq/ml

 

MonFCH

Tracer for use with positron emission tomography (PET) in detection of bone metastases of prostate cancer and hepatocellular carcinoma
Summary of Product Characteristic
MonFCH 910-3415 MBq/ml
 

 

Natrii fluoridum (18F) Synektik

Tracer for use with positron emission tomography (PET) in diseases where abnormally altered osteogenic activity is the diagnostic target
Summary of Product Characteristic
Natrii fluoridum (18F) Synektik 2.0 GBq/ml